Halyard Health, Inc. (HYH) Downgraded by TheStreet
Other equities analysts have also recently issued research reports about the company. Stifel Nicolaus restated a buy rating and issued a $45.00 price target on shares of Halyard Health in a report on Thursday, September 21st. Zacks Investment Research upgraded Halyard Health from a hold rating to a buy rating and set a $44.00 price target for the company in a report on Wednesday, July 12th. Stephens upgraded Halyard Health from an equal weight rating to an overweight rating in a report on Thursday, August 3rd. Deutsche Bank AG upped their price target on Halyard Health from $35.00 to $42.00 and gave the stock a buy rating in a report on Thursday, August 3rd. Finally, BidaskClub cut Halyard Health from a buy rating to a hold rating in a report on Saturday, July 8th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $42.25.
Halyard Health (NYSE:HYH) last released its quarterly earnings results on Tuesday, October 31st. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.47 by $0.13. The firm had revenue of $401.40 million during the quarter, compared to analysts’ expectations of $394.54 million. Halyard Health had a return on equity of 8.29% and a net margin of 3.06%. Halyard Health’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.48 EPS.
COPYRIGHT VIOLATION WARNING: “Halyard Health, Inc. (HYH) Downgraded by TheStreet” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://theolympiareport.com/2017/11/02/halyard-health-inc-hyh-downgraded-by-thestreet.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. American Century Companies Inc. boosted its stake in shares of Halyard Health by 181.5% during the 3rd quarter. American Century Companies Inc. now owns 121,628 shares of the medical instruments supplier’s stock valued at $5,477,000 after buying an additional 78,423 shares during the last quarter. State of Tennessee Treasury Department purchased a new position in shares of Halyard Health during the 3rd quarter valued at approximately $4,953,000. Chicago Equity Partners LLC boosted its stake in shares of Halyard Health by 96.2% during the 3rd quarter. Chicago Equity Partners LLC now owns 272,704 shares of the medical instruments supplier’s stock valued at $12,280,000 after buying an additional 133,699 shares during the last quarter. Wedge Capital Management L L P NC boosted its stake in shares of Halyard Health by 13.6% during the 3rd quarter. Wedge Capital Management L L P NC now owns 14,308 shares of the medical instruments supplier’s stock valued at $644,000 after buying an additional 1,716 shares during the last quarter. Finally, Crossmark Global Holdings Inc. purchased a new position in shares of Halyard Health during the 3rd quarter valued at approximately $280,000. Hedge funds and other institutional investors own 91.03% of the company’s stock.
About Halyard Health
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.